IL122266A - Method and a kit for determining metastatic potential of a tumor of epithelial cell origin - Google Patents

Method and a kit for determining metastatic potential of a tumor of epithelial cell origin

Info

Publication number
IL122266A
IL122266A IL12226696A IL12226696A IL122266A IL 122266 A IL122266 A IL 122266A IL 12226696 A IL12226696 A IL 12226696A IL 12226696 A IL12226696 A IL 12226696A IL 122266 A IL122266 A IL 122266A
Authority
IL
Israel
Prior art keywords
tumor
kit
epithelial cell
metastatic potential
cell origin
Prior art date
Application number
IL12226696A
Other languages
English (en)
Other versions
IL122266A0 (en
Original Assignee
George Washington University S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,203 external-priority patent/US5830640A/en
Application filed by George Washington University S filed Critical George Washington University S
Publication of IL122266A0 publication Critical patent/IL122266A0/xx
Publication of IL122266A publication Critical patent/IL122266A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
IL12226696A 1995-06-07 1996-06-06 Method and a kit for determining metastatic potential of a tumor of epithelial cell origin IL122266A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/486,203 US5830640A (en) 1995-03-07 1995-06-07 Determining invasiveness of prostatic adenocarcinoma
US08/658,796 US5935860A (en) 1995-03-07 1996-06-05 Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
PCT/US1996/010221 WO1996040657A1 (en) 1995-06-07 1996-06-06 Inhibitors of phospholipase a¿2?

Publications (2)

Publication Number Publication Date
IL122266A0 IL122266A0 (en) 1998-04-05
IL122266A true IL122266A (en) 2005-11-20

Family

ID=27048610

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12226696A IL122266A (en) 1995-06-07 1996-06-06 Method and a kit for determining metastatic potential of a tumor of epithelial cell origin

Country Status (7)

Country Link
US (5) US5935860A (xx)
EP (1) EP0840729A4 (xx)
JP (2) JPH11507644A (xx)
AU (1) AU6174696A (xx)
CA (1) CA2223878A1 (xx)
IL (1) IL122266A (xx)
WO (1) WO1996040657A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
US6255281B1 (en) * 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20020160948A1 (en) * 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2001080872A1 (en) * 2000-04-21 2001-11-01 George Washington University Method of binding integrin for treatment of cancer
EP1300159B1 (en) * 2000-06-29 2007-10-10 Anthera Pharmaceuticals, Inc. Remedies for cancer
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030211538A1 (en) * 2001-12-03 2003-11-13 Ming Luo CAP-Gly domain structure and uses thereof
AUPS282602A0 (en) * 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
AU2003290988A1 (en) * 2002-11-14 2004-06-15 Pintex Pharmaceuticals, Inc. Levels of pin1 in normal and cancerous tissue
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
CN1946906A (zh) * 2004-04-29 2007-04-11 吉斯通护岸系统股份有限公司 用于墙、护墙和类似物的饰面
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
JP2009502807A (ja) * 2005-07-22 2009-01-29 ミリアド ジェネティクス， インコーポレイテッド 薬剤含有率の高い製剤および投与量形態
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
AU2010284036B2 (en) 2009-08-21 2014-12-18 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
CN102834115B (zh) 2009-10-15 2015-01-14 克拉莱森公司 用于治疗流感的重组人cc10蛋白
MX2012009088A (es) 2010-02-04 2012-12-05 Gilead Biologics Inc Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
EP2407555A1 (en) 2010-07-14 2012-01-18 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Methods and kits for the diagnosis of prostate cancer
EP2407554A1 (en) 2010-07-14 2012-01-18 Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron Methods and kits for the diagnosis of prostate cancer
JP2014507163A (ja) * 2011-02-24 2014-03-27 ヴェンタナ メディカル システムズ， インク． 前立腺生検における低悪性度ｐｉｎ（ｌｇ−ｐｉｎ）におけるｅｒｇ遺伝子再構成の存在とタンパク質過剰発現

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489166A (en) * 1982-05-27 1984-12-18 Research Corporation Monitoring of human endometrial function by radioimmunoassay of PEP
US5266562A (en) * 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5219752A (en) * 1988-05-25 1993-06-15 Teijin, Limited Process for continuously culturing adherent animal cells
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5132315A (en) * 1989-05-19 1992-07-21 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic application of an anti-invasive compound
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
DE3937607A1 (de) * 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
CA2094203A1 (en) * 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5935860A (en) * 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers

Also Published As

Publication number Publication date
JP2008156353A (ja) 2008-07-10
US5935860A (en) 1999-08-10
EP0840729A1 (en) 1998-05-13
IL122266A0 (en) 1998-04-05
AU6174696A (en) 1996-12-30
US6316416B1 (en) 2001-11-13
WO1996040657A1 (en) 1996-12-19
US6054320A (en) 2000-04-25
US6335321B1 (en) 2002-01-01
CA2223878A1 (en) 1996-12-19
JPH11507644A (ja) 1999-07-06
US6395715B1 (en) 2002-05-28
EP0840729A4 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
IL122266A (en) Method and a kit for determining metastatic potential of a tumor of epithelial cell origin
AU1610299A (en) Method of cancer cell detection
EP0738891A3 (en) Protein detection method and kit using this method
AU2582195A (en) Method of detecting cancer involving fragments of cytokeratin 18 and corresponding antibodies
AU7358298A (en) Method of detecting metastatic thyroid cancer
IL123451A0 (en) Method and kit for the detection of explosives
IL115506A0 (en) Method of analyzing cell mitosis
AUPP278698A0 (en) Method of cell nuclei segmentation
AU6542196A (en) Volumetric cell quantification method and system
CA2147897A1 (en) Well characterization method
IL119770A0 (en) Circuit and method for determining time of arrival
AU696638B2 (en) Method of assaying antiphospholipid antibody and kit therefor
EG21026A (en) Method of charging ore
AU6128794A (en) Methods and kits for determining effects of anti-cancer agents on cancer cells
EP0744468A4 (en) METHOD FOR DETERMINING POTASSIUM IONS
AU5164696A (en) Measurement of environmental parameters in concrete
GB9501221D0 (en) Continuity tester and method
EP1029243A4 (en) METHOD FOR DETERMINING VOLUME-HYPERTENSION AND APPROPRIATE APPARATUS
AU7035598A (en) Method of measuring particle sizes
IL114938A0 (en) Reagent for determining water and ene-diols or thiols
AU7342396A (en) Ethene meter and method for determining the amount of ethene in a gas
GB2299864B (en) Method for determining the type and/or amount of an electrochemically convertible substance in a gas sample
AU6551398A (en) Method of detecting prostate cancer metastasis
GB9522756D0 (en) Cell line and method
AU2002300747A1 (en) Method and construct for inhibition of cell migration

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees